Clinics and research in hepatology and gastroenterology · 2026
Efficacy and safety of empagliflozin in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Samajdar Shambo Samrat, Joshi Shashank R, Bhaduri Gaurab, Saboo Banshi, Roy Krishnendu, Mukherjee Shatavisa, Bansode Snehal, Bandyopadhyay Sanjay
Аннотация
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading cause of chronic liver disease and is tightly linked to obesity, insulin resistance and type 2 diabetes. There are limited drugs approved for MASLD, creating an urgent need to repurpose agents with favourable metabolic and organ-protective profiles. Empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor with established cardiovascular and renal benefits, has emerged as a promising candidate, but trial-level evidence remains fragmented.
METHODS: We performed a systematic review and meta-analysis of randomized controlled trials evaluating empagliflozin in adults with imaging-confirmed MASLD or related entities. Searches of PubMed/MEDLINE, Embase, Web of Science, Scopus, and major trial registries were conducted. Continuous outcomes were pooled as mean differences (MD) using mixed-effects models. Risk of bias and certainty of evidence were formally assessed.
RESULTS: Eight RCTs were included. Empagliflozin significantly reduced liver fat content (MD -2.47%, 95% CI -3.79 to -1.16) and liver stiffness (MD -0.49 kPa, 95% CI -0.89 to -0.09). Alanine aminotransferase and aspartate aminotransferase (MD -4.85 U/L, -9.21 to -0.49) declined, while aspartate aminotransferase-to-platelet ratio index improved (MD -0.03, 95% CI -0.05 to -0.00). Body mass index, visceral adipose tissue and truncal fat mass fell significantly with preservation of skeletal muscle index. Fasting glucose improved, whereas homeostatic model assessment of insulin resistance, low-density lipoprotein cholesterol, and triglycerides remained neutral. Safety profiles were consistent with established SGLT2 inhibitor experience, with no hepatic safety signals.
CONCLUSION: Empagliflozin confers coherent improvements in hepatic steatosis, fibrosis surrogates, insulin resistance and visceral adiposity in MASLD, without new safety concerns, supporting its further evaluation as a potential adjunctive therapeutic option for MASLD.
METHODS: We performed a systematic review and meta-analysis of randomized controlled trials evaluating empagliflozin in adults with imaging-confirmed MASLD or related entities. Searches of PubMed/MEDLINE, Embase, Web of Science, Scopus, and major trial registries were conducted. Continuous outcomes were pooled as mean differences (MD) using mixed-effects models. Risk of bias and certainty of evidence were formally assessed.
RESULTS: Eight RCTs were included. Empagliflozin significantly reduced liver fat content (MD -2.47%, 95% CI -3.79 to -1.16) and liver stiffness (MD -0.49 kPa, 95% CI -0.89 to -0.09). Alanine aminotransferase and aspartate aminotransferase (MD -4.85 U/L, -9.21 to -0.49) declined, while aspartate aminotransferase-to-platelet ratio index improved (MD -0.03, 95% CI -0.05 to -0.00). Body mass index, visceral adipose tissue and truncal fat mass fell significantly with preservation of skeletal muscle index. Fasting glucose improved, whereas homeostatic model assessment of insulin resistance, low-density lipoprotein cholesterol, and triglycerides remained neutral. Safety profiles were consistent with established SGLT2 inhibitor experience, with no hepatic safety signals.
CONCLUSION: Empagliflozin confers coherent improvements in hepatic steatosis, fibrosis surrogates, insulin resistance and visceral adiposity in MASLD, without new safety concerns, supporting its further evaluation as a potential adjunctive therapeutic option for MASLD.